BE THE NEW

(Senior) Immunogenicity Technologist

in a biotech company focused on the discovery, design and development of innovative peptide-based medicines

Currently, we are looking for a new (senior) immunogenicity technologist, who has experience in ligand binding and cell-based assay development and qualification. If this sounds like you, and if you are ready to take on a broad area of responsibilities with an independent attitude, you are a match for us.

The position is placed in the Immunogenicity team in the Department of Bioanalysis and Pharmacokinetics. Our Immunogenicity team supports our drug development projects with assays to detect and characterize potential immunogenicity of our new peptide drugs during the development phases. Key responsibilities are the development of high-quality anti-drug antibody (ADA) and neutralizing antibody (NAb) assays as well as supporting smooth transfer and validation of the assays at contract research organizations (CROs). You will also be involved in generating and characterizing critical reagents used for our assays. The Department of Bioanalysis and Pharmacokinetics consists of 15 dedicated assay specialists collaborating to understand the fate of our drug candidates when dosed to patients.

Responsibilities

Development and qualification of cell-based neutralizing antibody assays
Development and qualification of ligand binding anti-drug antibody assays
Cell culture maintenance
Production and purification of critical reagents
Characterization of critical reagents
Support the transfer of in-house developed assays to our CROs
Data analysis and documentation
Maintenance of equipment

Candidate profile

Laboratory technician or B.Sc. with documented experience within immunochemistry
Experienced in development and qualification of cell-based neutralizing and ligand binding antibody assays
Preferably experienced in setting up assays to monitor drug-induced immunogenicity
Independent and highly motivated
Good documentation skills
Good collaborator
Confident in written and oral communication in English

Bonding to innovate 

Our employees are fundamental to our success, and we continue to be able to attract and retain people with vast experience and talent. We have a unique culture, characterized by excellent teamwork and strong engagement across the organization.

Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other.

We bond as a result of our entrepreneurial culture where our people are encouraged to pursue their ideas and turn them into reality. We are curious about each other’s knowledge and expertise.

We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Zealand Pharma is a place where everyone is heard and contributes to the success, we all want to experience.

The Zealand Pharma DNA builds on four values: (1) We are bold, (2) We empower people, (3) We work as one team, and (4) We can be trusted.

Let’s bond and be bold 

We offer a combined compensation package which includes a base salary, pension, bonus, and a possibility to join our employee share program. We care about our employees’ well-being and offer health insurance, use of massage, fitness, and a range of social clubs and activities

To find out more about working at Zealand, visit https://www.zealandpharma.com/careers/zealand-as-a-workplace/

Interested? Please apply no later than September 15, 2024, or as soon as possible. The applications will be reviewed as they come in.

For further information, please contact Carsten Boye Knudsen CKnudsen@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a Danish biotechnology company on a mission to change lives with next generation peptide medicines. In our effort to reach our goals bonding is at the core of everything we do. Let it be discovering and developing the best new peptide drugs for patients, engaging with partners or connecting with each other. This has led to more than 10 drug candidates invented by Zealand having advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Additionally, the portfolio includes clinical license collaboration with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals. Zealand is based in Copenhagen (Søborg), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or bond with us through LinkedIn.